Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Cancers · 05.04.2026 · 18 (7) · 1170
DOI: 10.3390/cancers18071170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 05.04.2026. Verfasst von Şahin Bedir und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gaziosmanpaşa Hastanesi, Istinye University, 34010 Istanbul, Turkey. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced non-small cell lung cancer (NSCLC), yet substantial heterogeneity in clinical outcomes persists. Easily accessible biomarkers that can reliably stratify prognosis in real-world practice are still lacking. The Lung Immune Prognostic Index (LIPI), integrating lactate dehydrogenase (LDH) and the derived neutrophil-to-lymphocyte ratio (dNLR), has emerged as a promising candidate, yet its clinical relevance remains incompletely defined.
Methods
We conducted a multicenter retrospective analysis of 211 patients with metastatic NSCLC treated with second-line nivolumab between 2017 and 2025. Patients were categorized into three groups (good, intermediate, and poor) according to their LIPI score, and the relationships between LIPI and objective response, disease control, progression-free survival (PFS), and overall survival (OS) were analyzed.
Results
LIPI stratification effectively discriminated patients into prognostically distinct groups. Objective response rates were comparable across LIPI categories and did not differ significantly. In contrast, disease control declined progressively with worsening LIPI scores, reaching statistical significance (p < 0.001). Overall survival was significantly worse in patients with poor LIPI, demonstrating a clear stepwise reduction from good to poor LIPI groups (p = 0.007). Although progression-free survival showed a consistent numerical decrease across LIPI categories, this trend did not achieve statistical significance.
Conclusions
In patients with metastatic NSCLC receiving second-line nivolumab in a real-world setting, LIPI reliably stratified overall survival and disease control outcomes, despite limited association with early response or progression-free survival. Its simplicity and reliance on routinely available laboratory parameters support its use as a clinically meaningful prognostic tool in everyday practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gaziosmanpaşa Hastanesi, Istinye University, 34010 Istanbul, Turkey.
- İstanbul Başakşehir Çam ve Sakura Şehir Hastanesi, 34480 Istanbul, Turkey.
- Cerrahpasa Medical Faculty Hospital, Istanbul University-Cerrahpasa, 34320 Istanbul, Turkey.
- İstanbul Prof. Dr. Cemil Taşcioğlu Şehir Hastanesi, 34384 Istanbul, Turkey.
- Topkapi Liv Hospital, Faculty of Medicine, Istinye University, 34010 Istanbul, Turkey.
ORCID-Profile: Şahin Bedir, Tanju Kapağan, Hamza Abbasov, Nilüfer Bulut, Gökmen Umut Erdem
Zitieren
APA
Bedir, Ş., Kapağan, T., Bozkaya, Y., Oyman, A., Fidan, M. C., Guliyev, M., Abbasov, H., Demirci, N. S., Yıldırım Doğan, H. G., Çelik, E., Bulut, N., & Erdem, G. U. (2026). Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers, 18(7), 1170. https://doi.org/10.3390/cancers18071170
Vancouver
Bedir Ş, Kapağan T, Bozkaya Y, Oyman A, Fidan MC, Guliyev M, et al. Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers. 2026;18(7):1170. doi:10.3390/cancers18071170
BibTeX
@article{Bedir2026,
author = {Bedir, Şahin and Kapağan, Tanju and Bozkaya, Yakup and Oyman, Abdilkerim and Fidan, Mehmet Cem and Guliyev, Murad and Abbasov, Hamza and Demirci, Nebi Serkan and Yıldırım Doğan, Hale Gülçin and Çelik, Emir and Bulut, Nilüfer and Erdem, Gökmen Umut},
title = {Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1170},
doi = {10.3390/cancers18071170}
}
EUVIMED